RSV Vaccine Statistics in US 2025 | RSV Shot in Adults

RSV Vaccine in America 2025

The respiratory syncytial virus vaccine landscape in America has undergone remarkable transformation throughout 2025, marking a pivotal year in public health protection against this serious respiratory illness. Following the initial approval of RSV vaccines for adults in 2023, the 2024-2025 respiratory season represented the first full implementation period where comprehensive vaccination data became available across diverse population segments. The Centers for Disease Control and Prevention now tracks multiple data streams including National Immunization Survey coverage estimates, retail pharmacy administration records, and Medicare claims data to provide Americans with transparent insights into vaccination progress nationwide.

Throughout 2025, federal health authorities expanded recommendations to include all adults aged 75 years and older plus adults aged 50-74 years with increased risk conditions, while pregnant women between 32-36 weeks gestation received guidance to protect newborn infants through maternal immunization. Despite these clear recommendations backed by substantial clinical evidence showing 75-83% effectiveness against severe disease, vaccination uptake remains suboptimal with only 47.5% of eligible adults aged 75+ reporting vaccination as of April 2025 according to National Immunization Survey data. This comprehensive examination of RSV vaccine statistics reveals both encouraging progress and persistent challenges that demand continued public health attention throughout the 2025-2026 respiratory season now underway.

Latest RSV Vaccine Facts and Statistics in the United States 2025

Data source: Centers for Disease Control and Prevention, RSVVaxView Dashboard, National Immunization Survey-Adult COVID Module, IQVIA healthcare claims database, Vaccine Safety Datalink surveillance system, and New England Journal of Medicine systematic review, accessed November 2025

The latest statistics from 2025 paint a detailed picture of RSV vaccination progress across the United States, revealing both achievements and areas requiring improvement. The 47.5% vaccination coverage among adults 75 and older as of April 2025 represents substantial progress from earlier in the season, yet falls considerably short of optimal public health targets that could prevent tens of thousands of hospitalizations annually. This coverage rate reflects an increase from 28.8% recorded earlier in the 2024-2025 season, demonstrating gradual but steady uptake throughout the respiratory virus period. Particularly concerning are the vaccination rates among high-risk adults aged 60-74 years, where only 38.1% have received protection despite facing elevated risks from chronic conditions like heart disease, lung disease, and diabetes.

The cumulative administration of 6.26 million doses through retail pharmacies for adults 75+ through April 2025 demonstrates significant healthcare system engagement, with an additional 7.84 million doses administered to adults aged 60-74 years during the same period. Medicare data reveals that 31.5% of fee-for-service beneficiaries aged 75+ enrolled in Part D plans received vaccination by February 2025, though this metric shows substantial variation across demographic groups. The maternal RSV vaccination program achieved 38.5% coverage among eligible pregnant women at 32+ weeks gestation through January 2025. Real-world effectiveness data from the 2023-2024 season confirms that RSV vaccines deliver on their promise, with Arexvy demonstrating 77% effectiveness against emergency department encounters and 83% effectiveness against hospitalizations among adults 60 and older, while a comprehensive systematic review published in the New England Journal of Medicine in 2025 confirmed that RSV vaccines in adults 60+ showed 68% or higher effectiveness against hospitalization.

RSV Vaccination Coverage by Demographics in the United States 2025

Data source: Centers for Disease Control and Prevention RSVVaxView Dashboard, Medicare Fee-for-Service administrative claims data, and Vaccine Safety Datalink, accessed November 2025

Demographic disparities in RSV vaccination coverage represent one of the most concerning findings from 2025 surveillance data, highlighting systemic barriers that prevent equitable protection across American populations. Among Medicare fee-for-service beneficiaries aged 75 and older, White non-Hispanic individuals achieved 32.6% coverage while Hispanic beneficiaries languished at just 10.7% as of February 2025, revealing a troubling threefold disparity that demands immediate public health intervention. These gaps extend beyond race and ethnicity to encompass multiple social determinants of health including disability status, health insurance coverage, poverty levels, and geographic urbanicity.

The maternal RSV vaccination program similarly demonstrates stark racial and ethnic disparities that threaten infant health equity across America. Non-Hispanic Asian pregnant women achieved the highest coverage at 52.6% through January 2025, more than double the 25.7% coverage observed among non-Hispanic Black pregnant women during the same surveillance period. These disparities reflect complex interactions between healthcare access barriers, provider recommendation patterns, vaccine confidence levels, and structural racism within medical systems. The CDC National Immunization Survey data reveals that vaccination coverage also varies significantly by presence of chronic medical conditions, with paradoxical findings suggesting that some high-risk individuals remain undervaccinated despite their elevated susceptibility to severe RSV disease. Addressing these demographic disparities requires targeted outreach campaigns, culturally competent education materials, expanded access points in underserved communities, and systematic efforts to build trust between healthcare providers and marginalized populations throughout the United States in 2025.

RSV Vaccine Distribution and Administration Patterns in the United States 2025

Data source: IQVIA healthcare claims database, CDC Immunization Information Systems, and CDC RSVVaxView Dashboard, accessed November 2025

The distribution patterns of RSV vaccines throughout America in 2025 reveal the central role that retail pharmacies play in adult immunization infrastructure, with the vast majority of doses administered outside traditional physician office settings. IQVIA claims data demonstrates that retail pharmacies delivered approximately 6.26 million doses to adults 75 and older cumulatively through April 2025, with 1.76 million of those doses administered during the 2024-2025 respiratory season since August 2024. In comparison, physicians’ medical offices contributed 145,350 cumulative doses to the same age group, with 55,010 doses given during the current season. This approximately 35-to-1 ratio of pharmacy to physician office administration underscores the critical importance of community pharmacies as vaccination access points.

Geographic variation in RSV vaccine coverage reveals substantial disparities across American jurisdictions, with state Immunization Information Systems data showing coverage among adults 75+ ranging from a low of 1.5% to a high of 47.9% through March 2025 among the 37 reporting state and city jurisdictions. Territorial and affiliated island jurisdictions demonstrated even lower coverage, ranging from 0% to 4.0% across seven reporting areas. These geographic differences reflect complex interactions between state-level policy environments, healthcare infrastructure density, population demographics, vaccine confidence levels, and provider recommendation practices. The three FDA-licensed RSV vaccines available in 2025 include GSK’s Arexvy (adjuvanted RSVPreF3), Pfizer’s Abrysvo (RSVpreF), and Moderna’s mResvia (mRNA-1345), with Arexvy comprising approximately 64% of doses administered according to Veterans Health Administration data. CDC guidance emphasizes that eligible adults can receive RSV vaccination at any time, though late summer and early fall represent optimal timing to ensure protection before the typical November through March peak season when RSV circulation reaches maximum intensity across most of the continental United States.

RSV Disease Burden and Hospitalization Trends in the United States 2025

Data source: CDC National Respiratory and Enteric Virus Surveillance System (NREVSS), CDC RSV-NET Hospitalization Surveillance Network, and CDC RSV disease burden estimates, accessed November 2025

The RSV disease burden throughout the 2024-2025 respiratory season demonstrated concerning patterns that underscore the continued threat this virus poses to American public health despite new immunization tools. National Respiratory and Enteric Virus Surveillance System data reveals that RSV test positivity spiked dramatically during the winter holiday period, reaching a peak of 10.97% during the week of December 21, 2024, and remaining above 10% threshold well into January 2025. This sustained elevated circulation occurred precisely when families gathered for Thanksgiving, Christmas, and New Year celebrations, creating ideal transmission conditions in indoor environments. While this peak represented a slight improvement compared to the 12.75% peak observed during the 2023-2024 season, the prolonged duration of elevated positivity rates maintained substantial community disease burden.

Hospitalization surveillance through the RSV-NET network documented peak rates of 3.9 hospitalizations per 100,000 individuals during early January 2025, with substantially higher burdens among adults aged 65 and older who face the greatest risks from severe RSV lower respiratory tract disease. Historical CDC estimates suggest that RSV causes approximately 6,000 to 10,000 deaths annually among American adults 65 and older, alongside 60,000 to 160,000 hospitalizations in this vulnerable age group. The 2024-2025 season showed some encouraging signs of reduced burden compared to the prior year, with peak hospitalization rates declining from 4.5 per 100,000 to 3.9 per 100,000, potentially reflecting early impacts of adult RSV vaccination programs that began in 2023. However, the pattern of hospitalization decline proved more gradual during the 2024-2025 season compared to the more rapid decline observed in 2023-2024, suggesting complex epidemiological dynamics. CDC modeling indicates that optimal RSV vaccine uptake could prevent 35-64% of RSV-associated hospitalizations, translating to tens of thousands of prevented hospitalizations and billions in avoided healthcare costs if coverage targets were achieved across eligible populations in the United States.

RSV Vaccine Effectiveness and Real-World Performance in the United States 2025

Data source: CDC real-world effectiveness studies, New England Journal of Medicine systematic review, Veterans Health Administration research published in JAMA Internal Medicine November 2025, and FDA clinical trial data, accessed November 2025

Real-world effectiveness data emerging throughout 2025 confirms that RSV vaccines deliver substantial protection against serious outcomes, validating the public health investment in these immunization programs. The most comprehensive effectiveness evidence comes from CDC’s evaluation of Arexvy during the 2023-2024 RSV season, demonstrating 77% effectiveness in preventing RSV-associated emergency department encounters and 83% effectiveness in preventing RSV-associated hospitalizations among adults aged 60 and older. These real-world estimates closely align with clinical trial efficacy data, providing confidence that vaccine performance translates effectively from controlled research settings to routine clinical practice across diverse American populations. A systematic review published in the New England Journal of Medicine in 2025 synthesized evidence across all licensed RSV immunizations, confirming that RSV vaccines in adults 60 years and older consistently demonstrated 68% or higher effectiveness against hospitalization outcomes.

However, emerging evidence from the Veterans Health Administration published in JAMA Internal Medicine in November 2025 raises important questions about the durability of RSV vaccine protection over time. This landmark study analyzing 301,300 vaccinated veterans matched with over one million controls found that while RSV vaccination remained effective in preventing illness and healthcare utilization, protection notably decreased across two respiratory seasons spanning 18 months of follow-up. The decline in effectiveness proved particularly pronounced among immunocompromised individuals, suggesting that certain high-risk populations may benefit from additional vaccine doses to maintain optimal protection. Among the study participants, 64% received Arexvy (RSVPreF3) while 35.2% received Abrysvo (RSVpreF), providing comparative real-world data on both major vaccine products. These findings prompted researchers to recommend that the Advisory Committee on Immunization Practices review whether additional vaccine doses might benefit specific risk groups, though current CDC recommendations in 2025 specify RSV vaccination as a single lifetime dose for eligible adults. The maternal RSV vaccine Abrysvo demonstrated 81.1% effectiveness against severe RSV lower respiratory tract infection in infants within 90 days of birth and 69.4% effectiveness through 180 days in the pivotal MATISSE clinical trial, while nirsevimab antibody provides approximately 80% reduction in severe RSV disease risk for infants throughout their first season.

RSV Vaccine Safety Profile and Adverse Events in the United States 2025

Data source: CDC Vaccine Safety monitoring systems, FDA clinical trial safety data, New England Journal of Medicine systematic review, and CDC vaccine safety surveillance, accessed November 2025

The safety profile of RSV vaccines throughout 2025 surveillance confirms that these immunizations generally prove well-tolerated, with most adverse reactions remaining mild to moderate in severity and resolving without intervention. Common side effects reported after RSV vaccination include pain, redness, and swelling at the injection site, along with systemic symptoms such as fatigue, fever, headache, nausea, and muscle or joint pain that typically resolve within several days. Clinical trial data demonstrated that the frequency of serious adverse events among vaccinated groups proved similar to placebo groups, providing reassurance about overall vaccine safety. However, important safety signals require ongoing monitoring and transparent communication with healthcare providers and the public.

The most significant safety concern identified involves Guillain-Barré syndrome (GBS), a rare neurological condition affecting the peripheral nervous system that can cause muscle weakness and paralysis. A systematic review published in the New England Journal of Medicine in 2025 quantified the association, finding 18.2 excess cases of GBS per million doses of RSVpreF (Abrysvo) in older adults. Among adults 60 and older receiving Arexvy and Abrysvo, a small number developed serious neurologic conditions including GBS within 42 days after vaccination, though the limited number of cases made definitive causality difficult to establish. Notably, clinical trials of Moderna’s mResvia reported no cases of GBS within 42 days of vaccination among adults 60 and older. Despite this signal, the Advisory Committee on Immunization Practices and CDC continue to conclude that the benefits of RSV vaccination in reducing hospitalizations and deaths substantially outweigh potential risks for eligible populations.

For pregnant women receiving the maternal RSV vaccine Abrysvo, surveillance through 2025 examined concerns about preterm birth and pregnancy-related hypertension including preeclampsia. The systematic review analysis found no significant association between maternal RSV vaccination administered at 32-36 weeks gestation and preterm birth outcomes, providing reassurance about the safety of vaccination during the recommended pregnancy window. CDC recommends that RSV vaccines can be coadministered with other adult vaccines including seasonal influenza vaccine, with limited available data showing similar safety and reactogenicity profiles. Coadministration studies of Abrysvo with adjuvanted influenza vaccine demonstrated noninferiority compared to sequential administration in adults 65 and older, though fatigue rates increased somewhat with simultaneous administration. Ongoing safety monitoring through systems including V-Safe and the Vaccine Adverse Event Reporting System continues to track RSV vaccine safety throughout 2025 and into the 2025-2026 season.

Maternal RSV Vaccination and Infant Protection Programs in the United States 2025

Data source: CDC Vaccine Safety Datalink, CDC Immunization Information Systems data from 33 states and DC, and CDC maternal RSV vaccination surveillance, accessed November 2025

The maternal RSV vaccination program represents a groundbreaking strategy to protect America’s most vulnerable infants during their first months of life when RSV disease risk reaches peak intensity. CDC recommends a single dose of Pfizer’s Abrysvo vaccine for pregnant women during weeks 32 through 36 of gestation to confer passive immunity to newborns through transplacental antibody transfer. Surveillance data through January 2025 reveals that 38.5% of pregnant women at 32+ weeks gestation received RSV vaccination since the program began in September 2024, though substantial racial and ethnic disparities persist with non-Hispanic Asian women achieving 52.6% coverage while non-Hispanic Black women reached only 25.7% coverage during the same period.

Comprehensive infant protection strategies in the United States in 2025 offer two distinct pathways: maternal vaccination during pregnancy or administration of long-acting monoclonal antibodies (nirsevimab or clesrovimab) to infants directly. CDC guidance emphasizes that most babies need only one of these options for protection, not both. Analysis of infants born during October 2023 through March 2024 across 33 states and DC found that 28.9% received protection through either maternal vaccination (10.4%) or nirsevimab administration (18.5%) during the inaugural season. More recent estimates suggest infant protection levels increased to approximately 57.0% by March 2025 as programs matured and awareness grew. However, dramatic state-level variation persists, with coverage ranging from just 10.8% in Nevada to an impressive 53.1% in Vermont. The FDA approved clesrovimab as an additional monoclonal antibody option in 2025, and the Advisory Committee on Immunization Practices recommended it in August 2025 with no preferential recommendation between nirsevimab and clesrovimab. For the 2025-2026 respiratory season, federal health authorities discontinued routine use of palivizumab (effective December 31, 2025) in favor of the longer-acting newer products. The maternal RSV vaccine Abrysvo demonstrated remarkable immunogenicity in phase 2 trials, with vaccinated mothers showing 11-fold higher antibody levels against RSV-A and 14-fold higher against RSV-B at delivery compared to placebo, with substantial antibody transfer to infants providing crucial protection during the vulnerable early months.

RSV Vaccine Recommendations and Policy Updates for Adults in the United States 2025

Data source: CDC Advisory Committee on Immunization Practices recommendations, CDC clinical guidance documents, and HHS Secretary adoptions, accessed November 2025

The RSV vaccine recommendation landscape underwent significant evolution throughout 2025 as federal health authorities refined guidance to reflect emerging evidence and FDA approvals for expanded age groups. The foundational recommendation from the June 2024 ACIP meeting established universal RSV vaccination for all adults aged 75 years and older alongside risk-based recommendations for adults aged 60-74 years with conditions predisposing to severe disease. This marked an important shift from the initial 2023 “shared clinical decision-making” approach that left vaccination decisions to individual patient-provider discussions, toward clearer population-level recommendations that facilitate systematic implementation across healthcare settings. The list of high-risk conditions qualifying adults aged 50-74 years for vaccination includes chronic lung diseases, heart conditions, diabetes requiring insulin, immunocompromised states, solid organ or stem cell transplants, active cancer, liver disease, sickle cell disease or thalassemia, and nursing home residence.

In June 2025, ACIP voted to further expand RSV vaccine recommendations to include adults aged 50-59 years who have increased risk of severe RSV disease, a recommendation formally adopted by the HHS Secretary on June 25, 2025. This expansion recognizes that severe RSV outcomes occur across a broader age spectrum than initially appreciated, particularly among adults with underlying medical conditions. The FDA separately approved both Abrysvo (Pfizer) and mResvia (Moderna) for adults aged 18-49 years at increased risk for RSV lower respiratory tract disease, though as of February 2025, ACIP determined that insufficient evidence existed to inform a recommendation for this youngest adult age group. Current CDC guidance emphasizes that RSV vaccination represents a single lifetime dose, not an annual vaccine like influenza, meaning adults who received vaccination in 2023 or 2024 should not receive another dose in 2025. However, the Veterans Health Administration durability study published in November 2025 prompted discussions about whether certain immunocompromised populations might benefit from additional doses in future years. CDC permits and encourages coadministration of RSV vaccines with other age-appropriate immunizations including seasonal influenza and COVID-19 vaccines, though limited data suggests coadministration may result in slightly lower antibody levels with unknown clinical significance. Healthcare providers are instructed to accept patient attestation as sufficient evidence of risk factor presence without requiring medical documentation, removing a potential barrier to vaccination access. As the 2025-2026 respiratory season progresses, these refined recommendations aim to maximize protection across vulnerable American populations while surveillance systems continue gathering evidence to inform future policy refinements.

RSV Vaccine Access, Cost, and Insurance Coverage in the United States 2025

Access to RSV vaccines in the United States in 2025 has expanded significantly, with multiple coverage pathways available for adults and children. Medicare Part D fully covers RSV vaccines for adults aged 65 and older, making it the most reliable coverage option for seniors. While Medicare Part B offers limited coverage in specific clinical situations, most beneficiaries rely on their Part D prescription plans. Commercial insurance plans typically cover RSV vaccines under preventive care benefits, reducing out-of-pocket costs for many adults. Medicaid coverage varies by state, meaning eligibility and cost may differ depending on local policies.

For individuals without insurance, several safety-net programs improve access. State adult vaccine programs provide coverage for uninsured adults aged 19 and above, helping reduce financial barriers. For children, the Vaccines for Children (VFC) program covers preventive RSV products such as nirsevimab/clesrovimab for eligible infants and young children. Additionally, retail pharmacies across the country maintain widespread availability of all approved RSV vaccines, ensuring convenient access for the general population. Together, these coverage options support improved RSV prevention nationwide.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE